TRCT
BEAM icon

Tower Research Capital (TRC)’s Beam Therapeutics BEAM Stock Holding History

Tower Research Capital (TRC)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Sell
3,610
-2,092
-37% -$63.2K ﹤0.01% 2022
2026
Q1 		$136K Buy
5,702
+3,718
+187% +$103K ﹤0.01% 1936
2025
Q4 		$55K Sell
1,984
-73,310
-97% -$1.87M ﹤0.01% 2347
2025
Q3 		$1.83M Buy
75,294
+43,406
+136% +$864K 0.05% 315
2025
Q2 		$542K Buy
31,888
+16,935
+113% +$295K 0.01% 914
2025
Q1 		$292K Buy
14,953
+13,581
+990% +$356K 0.01% 1158
2024
Q4 		$34K Sell
1,372
-5,172
-79% -$132K ﹤0.01% 2813
2024
Q3 		$160K Sell
6,544
-21,819
-77% -$564K ﹤0.01% 1825
2024
Q2 		$665K Buy
28,363
+22,319
+369% +$548K 0.01% 1086
2024
Q1 		$200K Sell
6,044
-218
-3% -$6.79K ﹤0.01% 1413
2023
Q4 		$170K Buy
6,262
+2,168
+53% +$53.9K ﹤0.01% 2231
2023
Q3 		$98.5K Sell
4,094
-7,325
-64% -$196K ﹤0.01% 1990
2023
Q2 		$365K Buy
11,419
+5,759
+102% +$187K 0.01% 1176
2023
Q1 		$173K Buy
5,660
+4,090
+261% +$161K 0.01% 1448
2022
Q4 		$61K Sell
1,570
-32,893
-95% -$1.47M ﹤0.01% 2188
2022
Q3 		$1.64M Buy
34,463
+10,281
+43% +$586K 0.03% 495
2022
Q2 		$936K Buy
24,182
+1,433
+6% +$57K 0.02% 735
2022
Q1 		$1.3M Buy
22,749
+20,059
+746% +$1.32M 0.01% 701
2021
Q4 		$215K Sell
2,690
-1,626
-38% -$139K ﹤0.01% 1708
2021
Q3 		$376K Buy
4,316
+2,121
+97% +$213K 0.01% 1195
2021
Q2 		$283K Sell
2,195
-19,370
-90% -$1.54M 0.01% 1642
2021
Q1 		$1.73M Buy
21,565
+18,075
+518% +$1.72M 0.03% 535
2020
Q4 		$285K Sell
3,490
-14,349
-80% -$706K 0.01% 1431
2020
Q3 		$439K Buy
17,839
+15,225
+582% +$378K ﹤0.01% 1824
2020
Q2 		$73K Buy
+2,614
New +$56.3K ﹤0.01% 2739

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Tower Research Capital (TRC)'s BEAM Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Beam Therapeutics (BEAM) stake by 37% in Q2 2026, selling an estimated $63.2K and leaving 3,610 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Tower Research Capital (TRC) first reported a position in BEAM in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.83M in Q3 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Tower Research Capital (TRC) held 3,610 shares of Beam Therapeutics worth $124K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,092 Beam Therapeutics shares in Q2 2026, an estimated $63.2K.
  • Beam Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2022 holding.
  • Tower Research Capital (TRC) first reported a position in Beam Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Beam Therapeutics position peaked at $1.83M in Q3 2025.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.